Response to olaparib in a
Adult
Drug Resistance, Neoplasm
Fanconi Anemia Complementation Group N Protein
/ genetics
Germ-Line Mutation
High-Throughput Nucleotide Sequencing
Humans
Liver Neoplasms
/ drug therapy
Loss of Function Mutation
Male
Phthalazines
/ therapeutic use
Piperazines
/ therapeutic use
Precision Medicine
Prostatic Neoplasms
/ drug therapy
Retinoblastoma Binding Proteins
/ genetics
Sequence Analysis, DNA
Ubiquitin-Protein Ligases
/ genetics
prostate cancer
Journal
Cold Spring Harbor molecular case studies
ISSN: 2373-2873
Titre abrégé: Cold Spring Harb Mol Case Stud
Pays: United States
ID NLM: 101660017
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
07
11
2018
accepted:
08
02
2019
pubmed:
6
3
2019
medline:
9
4
2020
entrez:
6
3
2019
Statut:
epublish
Résumé
Prostate cancers harboring DNA repair gene alterations are particularly sensitive to PARP inhibitor treatment. We report a case of an advanced prostate cancer patient profiled within the NCT-MASTER (Molecularly Aided Stratification for Tumor Eradication Research) precision oncology program using next-generation sequencing. Comprehensive genomic and transcriptomic analysis identified a pathogenic germline
Identifiants
pubmed: 30833416
pii: mcs.a003657
doi: 10.1101/mcs.a003657
pmc: PMC6549578
pii:
doi:
Substances chimiques
Fanconi Anemia Complementation Group N Protein
0
PALB2 protein, human
0
Phthalazines
0
Piperazines
0
RB1 protein, human
0
Retinoblastoma Binding Proteins
0
Ubiquitin-Protein Ligases
EC 2.3.2.27
olaparib
WOH1JD9AR8
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2019 Horak et al.; Published by Cold Spring Harbor Laboratory Press.
Références
Nat Genet. 2007 Feb;39(2):159-61
pubmed: 17200672
Nature. 2007 Mar 15;446(7133):316-9
pubmed: 17287723
Science. 2009 Apr 10;324(5924):217
pubmed: 19264984
BMC Med Genet. 2010 Feb 02;11:20
pubmed: 20122277
N Engl J Med. 2014 Aug 7;371(6):497-506
pubmed: 25099575
Clin Cancer Res. 2014 Feb 15;20(4):890-903
pubmed: 24323898
Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7155-60
pubmed: 19369211
Hum Pathol. 2013 Aug;44(8):1617-23
pubmed: 23574779
Nat Genet. 2007 Feb;39(2):162-4
pubmed: 17200671
Clin Cancer Res. 1995 Jan;1(1):11-8
pubmed: 9815882
Cancer Res. 1997 Feb 1;57(3):524-31
pubmed: 9012485
Mol Cell. 2006 Jun 23;22(6):719-29
pubmed: 16793542
Oncology (Williston Park). 2017 Jun 15;31(6):467-74
pubmed: 28620903
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Prostate. 2002 Apr 1;51(1):59-72
pubmed: 11920959
Cancer Cell. 2013 Feb 11;23(2):159-70
pubmed: 23410972
J Med Genet. 2016 Dec;53(12):800-811
pubmed: 27595995
Nat Methods. 2011 Jun 12;8(8):652-4
pubmed: 21666668
Ann Oncol. 2017 Jan 1;28(1):142-148
pubmed: 27687311
Nat Genet. 2015 Jul;47(7):736-45
pubmed: 26005866
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
JAMA Oncol. 2015 Jul;1(4):466-74
pubmed: 26181256
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nat Rev Cancer. 2016 Feb;16(2):110-20
pubmed: 26775620
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Leukemia. 2016 Apr;30(4):937-46
pubmed: 26582644
Int J Cancer. 2017 Sep 1;141(5):877-886
pubmed: 28597939
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
Int J Urol. 2018 Apr;25(4):345-351
pubmed: 29396873